Novonesis stock (DK0060336014): new biosolutions giant emerges after Novozymes–Chr. Hansen merger

Enzyme specialist Novonesis, formed from the merger of Novozymes and Chr. Hansen, has published its first combined quarterly results and updated synergy targets. What the new biosolutions leader means for investors and how the business model works.

Novonesis, the new biosolutions group created from the merger of Novozymes and Chr. Hansen, has released its first combined quarterly figures and integration update, outlining organic growth trends and expected cost synergies for 2026 and beyond, according to a results announcement published on April 24, 2025 on the company’s investor website and reported the same day by Reuters as of 04/24/2025.

In that update, management highlighted mid?single?digit organic sales growth for the first quarter of 2025 and confirmed synergy targets from the merger, while also detailing integration progress across production, R&D and commercial activities, according to the company’s Q1 2025 report and presentation published on April 24, 2025 on its investor relations page and summarized by Nasdaq Copenhagen as of 04/24/2025.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis (formed from Novozymes and Chr. Hansen)
• Sector/industry: Biosolutions, industrial enzymes, microbial ingredients
• Headquarters/country: Denmark
• Core markets: Food and beverages, household care, bioenergy, agriculture, industrial applications
• Key revenue drivers: Enzymes for detergents and food, microbial solutions for agriculture and nutrition
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NVO or successor local ticker for the combined entity)
• Trading currency: Danish krone (DKK)

Novonesis: core business model

Novonesis operates as a focused biosolutions company built around industrial enzymes and microbial technologies that improve process efficiency and sustainability for its customers. The business model centers on selling high?value, knowledge?intensive ingredients that are typically used in relatively small quantities but have a large impact on performance and cost in customers’ products and manufacturing processes.

A key characteristic of this model is intensive research and development. Novonesis invests significantly in R&D to discover and optimize new enzymes and strains that can, for example, enable lower?temperature washing, increase yield in bioethanol production, or improve texture and shelf life in dairy products. These innovations are protected through intellectual property and long?term customer relationships, which can support pricing power and recurring revenue streams.

The company’s revenue is diversified across several end markets, including household care, food and beverage, bioenergy, agriculture and industrial applications. Many of these markets are linked to long?term structural trends such as the need to reduce energy consumption, cut emissions and move away from fossil?based chemistry. As a result, Novonesis positions its solutions not only as cost?effective but also as enablers of customers’ sustainability targets.

Novonesis primarily sells to business customers rather than directly to consumers, often working closely with large consumer goods companies, food manufacturers and industrial producers. These relationships can be complex and involve joint development projects, application testing and technical service, which increase switching costs for customers once a particular biosolution is embedded in their processes or product formulations.

Main revenue and product drivers for Novonesis

One of the main revenue pillars for Novonesis is enzymes for household care products, especially laundry detergents and dishwashing agents. These enzymes allow effective cleaning at lower temperatures and with smaller doses of chemicals, helping detergent makers differentiate their products while supporting environmental claims. This category has traditionally been among the most profitable for Novozymes and remains central to the combined group’s earnings profile.

Food and beverage applications form another major stream, ranging from enzymes that improve bread softness and volume to cultures and microbial solutions that enhance taste, texture and preservation in dairy and fermented foods. The legacy Chr. Hansen business brought a strong position in natural food cultures and probiotics, broadening Novonesis’ portfolio into health?oriented and clean?label ingredients that are in demand among global food producers.

Bioenergy, particularly enzymes for bioethanol production, represents a more cyclical but important segment. Here, Novonesis’ solutions help convert starch and other feedstocks into ethanol more efficiently, potentially boosting yield and reducing enzyme dosage per unit of fuel. Performance in this segment can be sensitive to policy frameworks, commodity prices and fuel demand, which investors often monitor as a source of earnings volatility relative to more stable food and household applications.

Agriculture and animal health are a further growth area. Microbial solutions and biological crop protection products can help improve plant health and nutrient use efficiency, offering an alternative or complement to synthetic fertilizers and pesticides. This ties Novonesis into broader trends in sustainable agriculture and regulatory pressure to reduce chemical inputs, particularly in Europe and increasingly in other regions.

Industrial biosolutions, including enzymes for textile processing, wastewater treatment and other niche uses, provide an additional diversification layer. These applications can vary in size and growth rate but often share a common theme: replacing or reducing harsh chemicals and energy?intensive steps with more resource?efficient biological processes, which can be attractive to industrial customers facing tightening environmental regulations.

Conclusion

Novonesis emerges from the combination of Novozymes and Chr. Hansen as a scaled specialist in enzymes and microbial solutions with exposure to multiple structural growth trends, from sustainable household care and food to bioenergy and agriculture. The first integrated results and synergy update following the merger provide early insight into how the new group intends to deliver cost and revenue benefits, while maintaining high R&D intensity and close customer partnerships. For US investors, the stock offers an avenue to participate in global demand for biosolutions and decarbonization technologies via a Danish?listed company, but it also comes with typical sector risks, including cyclicality in certain end markets, execution on integration and sensitivity to regulatory and commodity?price developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.